Achema middle east
Clinical Trials

DiaMedica completes enrollment in DM199 single ascending dose diabetes study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Clinical Trials

Modular and Portable Laboratory Equipment Supporting Flexible Pharma Operations

Modern pharmaceutical manufacturing demands adaptable infrastructure capable of rapid reconfiguration to accommodate changing production requirements, making modular and portable laboratory equipment essential for contract manufacturers, clinical trial operations, and organizations pursuing capacity expansion through scalable platform technologies.
Business & Industry

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
Clinical Trials

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
- Advertisement -

Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study.

The randomized study is designed to assess three dose levels each in type 2 diabetic patients. DiaMedica chairman and CEO Rick Pauls said, “Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway.”

The primary objective of the SAD portion of the ongoing study is acute safety, tolerability and pharmacokinetic properties for the first time in type 2 diabetic patients, in addition to the efficacy of DM199 on improving glucose control.

The top line results from the placebo-controlled, double-blinded study are expected to be available in the third quarter of 2013.

 

Latest stories

Previous article
Eli Lilly reports positive data from Phase III study of Cialis
Next article
Oramed recruits patients to study orally ingestible insulin capsule

Related stories

Clinical Trials

Modular and Portable Laboratory Equipment Supporting Flexible Pharma Operations

Modern pharmaceutical manufacturing demands adaptable infrastructure capable of rapid reconfiguration to accommodate changing production requirements, making modular and portable laboratory equipment essential for contract manufacturers, clinical trial operations, and organizations pursuing capacity expansion through scalable platform technologies.
Business & Industry

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
Clinical Trials

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
Business & Industry

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
liver health supplements for recovery

Liver Health in the Age of Processed Foods: What Supplements Can...

science backed natural weight loss methods

Science-Backed Natural Weight Loss Methods That Actually Work